Table of Contents:

1 Executive Summary
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Top-Down & Bottom-Up Approach
3.6 Market forecast
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Rising Prevalence of Major Depressive Disorder (MDD)
4.2.2 Growing Importance of Generics
4.2.3 Increasing Demand for Atorvastatin Intermediate
4.2.4 Rising Incidence of Chronic Diseases
4.3 Restraints
4.3.1 Rising Healthcare Cost
4.3.2 Unfavorable Drug Price Control Policies Across Various Countries
4.4 Opportunities
4.4.1 Entering Developing Economies
4.5 Market Trends
4.5.1 Introduction of Innovative Drugs
4.6 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Supply Chain Analysis
5.1.1 R&D
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-Sales Monitoring
5.2 Porter's Five Forces Analysis
5.2.1 Threat of New Entrants
5.2.2 Bargaining Power of Suppliers
5.2.3 Threat of Substitutes
5.2.4 Bargaining Power of Buyers
5.2.5 Intense Rivalry
5.3 Investment Opportunities
5.4 Pricing Analysis
5.5 Product Pipeline Analysis
5.5.1 Overview
5.5.2 Duloxetine (Cymbalta) for Dysthymic Disorder and Depressive Disorder NOS
5.5.3 Effect of Duloxetine for the Treatment of Chronic Pain due to Osteoarthritis
5.5.4 Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients with Chronic Pain
5.5.5 Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents with Depressive Disorder
5.5.6 Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy
5.5.7 Atorvastatin Calcium Tablets, 40 mg
5.5.8 Actual Use Trial of Atorvastatin Calcium 10 mg
5.5.9 Atorvastatin Vs. Simvastatin in the Prevention of Coronary Heart Disease (CHD) in Patients with Known CHD
5.5.10 Atorvastatin for the Treatment of Pulmonary Sarcoidosis
5.5.11 Atorvastatin for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women with Elevated Low-density Lipoprotein (LDL) Cholesterol
5.6 Specifications & Purity Requirements
5.7 Patent Analysis
5.7.1 Overview
5.7.2 Patent Analysis for the Process of Preparation of Duloxetine Intermediate and Atorvastatin Intermediate
5.7.2.1 Process for the Preparation of Duloxetine Hydrochloride and its Precursors
5.7.2.2 Process for Preparing 4-Chloro-3-Hydroxybutanoic Acid Ester
5.8 Regulatory Scenario
5.9 Manufacturing Processes
5.9.1 Duloxetine Intermediate
5.9.2 Atorvastatin Intermediate
5.1 Key Customers
6 Global Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
6.1 Overview
6.2 Duloxetine Intermediates
6.3 Atorvastatin Intermediates
7 Global Duloxetine Intermediate & Atorvastatin Intermediates Market, By Region
7.1 Overview
7.2 Americas
7.2.1 North America
7.2.1.1 US
7.2.1.2 Canada
7.2.2 Latin America
7.3 Europe
7.3.1 Western Europe
7.3.1.1 Germany
7.3.1.2 France
7.3.1.3 UK
7.3.1.4 Spain
7.3.1.5 Italy
7.3.1.6 Rest of Western Europe
7.3.2 Eastern Europe
7.4 Asia-Pacific
7.4.1 China
7.4.2 India
7.4.3 Japan
7.4.4 Rest of Asia-Pacific
7.5 Middle East & Africa
7.5.1 Middle East
7.5.2 Africa
8 Competitive Landscape
8.1 Introduction
9 Company Profiles
9.1 Jiangxi Aifeimu Technology Co., Ltd
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Products/Services Offered
9.1.4 Key Developments
9.1.5 SWOT Analysis
9.1.6 Key Strategies
9.2 Zhejiang Jiuzhou Pharmaceutical Co., Ltd
9.2.1 Company Overview
9.2.2 Financial Overview
9.2.3 Products/Services Offered
9.2.4 Key Developments
9.2.5 SWOT Analysis
9.2.6 Key Strategies
9.3 Jigs Chemicals
9.3.1 Company Overview
9.3.2 Financial Overview
9.3.3 Products/Services Offered
9.3.4 Key Developments
9.3.5 SWOT Analysis
9.3.6 Key Strategies
9.4 Manus Aktteva
9.4.1 Company Overview
9.4.2 Financial Overview
9.4.3 Products/Services Offered
9.4.4 Key Developments
9.4.5 SWOT Analysis
9.4.6 Key Strategies
9.5 Arch Pharmalabs
9.5.1 Company Overview
9.5.2 Financial Overview
9.5.3 Products/Services Offered
9.5.4 Key Developments
9.5.5 SWOT Analysis
9.5.6 Key Strategies
9.6 Afine Chemicals Ltd
9.6.1 Company Overview
9.6.2 Financial Overview
9.6.3 Products/Services Offered
9.6.4 Key Developments
9.6.5 SWOT Analysis
9.6.6 Key Strategies
9.7 Shodhana Laboratories
9.7.1 Company Overview
9.7.2 Financial Overview
9.7.3 Products/Services Offered
9.7.4 Key Developments
9.7.5 SWOT Analysis
9.7.6 Key Strategies
9.8 Fluorochem Ltd
9.8.1 Company Overview
9.8.2 Financial Overview
9.8.3 Products/Services Offered
9.8.4 Key Developments
9.8.5 SWOT Analysis
9.8.6 Key Strategies
9.9 Chiral Bio Sciences Ltd
9.9.1 Company Overview
9.9.2 Financial Overview
9.9.3 Products/Services Offered
9.9.4 Key Developments
9.9.5 SWOT Analysis
9.9.6 Key Strategies
9.1 Tokyo Chemical Industry Co., Ltd
9.10.1 Company Overview
9.10.2 Financial Overview
9.10.3 Products/Services Offered
9.10.4 Key Developments
9.10.5 SWOT Analysis
9.10.6 Key Strategies
10 Appendix
10.1 References
10.2 Related Reports